The KRAS gene mutations have been found above in 40 % of colorectal cancers and in 15–25 % of non-small cell lung cancer (NSCLC)—predominantly in patients with adenocarcinoma and smoking history [2, 4–6]. This evidence concerns the gene KRAS and adenocarcinoma.